Drug major Lupin's fourth quarter profit is expected to increase 32.7 percent to Rs 725.7 crore and revenue may rise 20 percent to Rs 3,816.3 crore compared to year-ago period, according to average of estimates of analysts polled by CNBC-TV18.
Strong operational performance and better US & India business may drive earnings growth during the quarter.
Operating profit (earnings before interest, tax, depreciation and amortisation) is seen rising 40 percent to Rs 1,105 crore and margin may expand 340 basis points to 29 percent compared to same period last fiscal.
Analysts feel exclusivity on Glumetza generic & full quarter of price hikes on Fortamet generic may drive US numbers.
Lupin launched Glumetza generic a diabetes drug in the US with 180-day exclusivity in February 2016 and acquired around 45 percent market share.
Contribution from Gavis (that acquired in July 2015) and seasonality from cephalosporin portfolio may also aid US business.
According to poll, India may continue to outperform with 18 percent growth and rest of the World Markets are likely to grow 20-22 percent led by consolidation of Mexican & Brazilian acquisitions. Japan may see 7-8 percent growth while South Africa business is likely to decline due to currency impact.
Commentary on observations at Goa plant will be a key factor to watch out for.
The stock lost 13 percent year-to-date because of observations on Goa plant.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
